Skip to main content

Tumor Ablation Market Set to Soar Past USD 4.08 Billion by 2030 | Skyquest Technology

The global Tumor Ablation market size is expected to reach USD 4.08 billion by 2030 and exhibit a CAGR of 13.5% in the forecast period (2023−2030), according to Skyquest’s latest research report. The technological advancements, increasing cancer prevalence, minimally invasive procedures, aging population, growing awareness, early cancer diagnosis, improving healthcare infrastructure, expanding applications, patient preference for less invasive treatments, reduced hospital stays, precision medicine, research and development, government support, rising demand for outpatient procedures are fueling the market’s growth.

Westford, USA, Jan. 29, 2024 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the Tumor Ablation Market, immunotherapy combination, MRI-guided ablation, AI and machine learning applications, 3D printing for personalized devices, telemedicine and remote consultations, focused ultrasound for non-invasive ablation, expanded use of microwave ablation, portable and handheld ablation devices, growing interest in irreversible electroporation, targeted therapies, are the trends that aid in the market’s growth.

Browse in-depth TOC on “Tumor Ablation Market”

  • Pages – 157
  • Tables – 95
  • Figures – 76

Tumor ablation is a minimally invasive procedure that uses heat, cold, or electricity to destroy tumor cells. It is a common treatment for a variety of cancers, including liver cancer, kidney cancer, lung cancer, and prostate cancer.

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/tumor-ablation-market

Prominent Players in Tumor Ablation Market

  • Medtronic
  • Boston Scientific
  • AngioDynamics
  • Galil Medical
  • HealthTronics
  • Stryker
  • NeuWave Medical
  • Insightec
  • EDAP TMS
  • Sonablate
  • BVM Medical
  • Terumo
  • IceCure Medical
  • AngioWave
  • Angiotech
  • Erbe Elektromedizin
  • Medtronic Minimally Invasive Therapies Group
  • Neuromodulation Systems
  • Olympus
  • Philips Healthcare
  • Siemens Healthineers
  • Sonacare Medical
  • Syneron Candela

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/tumor-ablation-market

Radiofrequency Ablation (RFA) Demand to Grow Substantially in the Forecast Period

Radiofrequency Ablation (RFA) dominates the global online market due to its proven clinical efficacy and versatility. It is widely used for treating various solid tumors, especially liver tumors. RFA is minimally invasive, relatively cost-effective, and provides excellent local tumor control.

Liver Cancer Ablation is the Leading Application Segment

In terms of application, liver cancer ablation is the leading segment as liver cancer is relatively common, and tumor ablation techniques like radiofrequency ablation and microwave ablation are effective and minimally invasive treatment options for this cancer type. Additionally, liver cancer patients may not be suitable candidates for surgery, making ablation a preferred choice.

North America is the leading Market Due to the Technological Advancements

Region-wise, North America is one of the largest growing markets with a huge emphasis on technological advancements. The region has a high incidence of cancer, a well-established healthcare system, a strong emphasis on cancer research and treatment, and a favorable regulatory environment. The presence of leading medical device companies and clinical research centers also contributes to North America’s prominence in the market.

A recent report thoroughly analyzes the major players operating within the Tumor Ablation market. This comprehensive evaluation has considered several crucial factors, such as collaborations, mergers, innovative business policies, and strategies, providing invaluable insights into the key trends and breakthroughs in the market. Additionally, the report has carefully scrutinized the market share of the top segments and presented a detailed geographic analysis. Finally, the report has highlighted the major players in the industry and their ongoing endeavors to develop innovative solutions that cater to the ever-increasing demand for Tumor Ablation.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/tumor-ablation-market

Key Developments in the Tumor Ablation Market

  • In April 2023, Angio Dynamics. announced an expanded partnership with Cardiva, a Spanish-based medical device company. The partnership builds on an existing collaboration between AngioDynamics and Cardiva, which has successfully distributed AngioDynamics’ vascular access portfolio in Spain and Portugal since 2012. The expanded partnership will now include AngioDynamics’ oncology portfolio, with the addition of the Italian market in the distribution agreement.

Key Questions Answered in Tumor Ablation Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • Can you list the top companies in the market and explain how they have achieved their positions of influence?
  • In what ways do regional trends and patterns differ within the global market, and how might these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Body Control Module Market

Global Muscle Stimulation Devices Market

Global Corneal Topographers Market

Global Oxygenator Market

Global Smart Diabetes Management Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.